骨髓抑制临床应用PEG-rhG-CSF专家共识及争议性问题探讨.pptVIP

Figure 1. Incidence of neutropenic events in the subsequent cycles according to the prophylactic strategy with or without G-CSF by the Kaplan-Meier curve for the time to recurrence of neutropenic event (N=548; all cycles)。 Figure 2. Incidence of neutropenic events in the subsequent cycles according to the type of G-CSF by the Kaplan-Meier curve for the time-torecurrence of neutropenic events (N=548; all cycles). rhG –CSF 支持与NE再发生的低风险相关（HR：0.32, P＜ 0.001）。 PEG-rhG-CSF 提供最有效的保护效应（HR=0.23，P＜ 0.001 ） 因此，二级预防应用G-CSF对于减少NE的发生有显著的效果，因而是合理的选择。 如果二级预防后仍出现FN或3/4度粒细胞减少，需要进行化疗减量或者调整化疗方案 治疗性应用 对于接受预防性使用P